Fig. 3: Determination of the potency for a subset of identified compounds. | Nature Communications

Fig. 3: Determination of the potency for a subset of identified compounds.

From: A high-throughput screen for TMPRSS2 expression identifies FDA-approved compounds that can limit SARS-CoV-2 entry

Fig. 3: Determination of the potency for a subset of identified compounds.

A selection of six of the most promising drugs were assessed for their activity (IC50) to inhibit TMPRSS2 expression extracellularly (first column) or to inhibit total TMPRSS2 (middle column) in TMPRSS2-HiBiT-BEAS-2B cells. An assessment of cellular toxicity for each compound (CellTiter-Glo) is shown in the last column. The remaining activity profiles for other identified agents are found in the supplementary figures. Data are mean ± SEM (n = 4 biologically independent samples). Data are plotted along with a sigmoidal model fit, with dotted lines representing the 95% confidence interval. Estimated values of IC50 and CC50 (cytotoxicity concentration 50%) are shown.

Back to article page